Type 2 Diabetes Clinical Trial
Official title:
A Single-Center, Open-Label, Randomized, Single-Dose, Two-Period, Two-Sequence, Crossover Study to Assess the Bioequivalence of Test Formulation With Reference Formulation in Healthy Adult Subjects.
Verified date | February 2019 |
Source | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Bioequivalence Study of Empagliflozin Tablets and Jardiance® Under Fasting and Fed Conditions in Chinese Healthy Volunteers.
Status | Completed |
Enrollment | 48 |
Est. completion date | May 25, 2018 |
Est. primary completion date | May 25, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: 1. Healthy male or female, age 18 to 50 years, inclusive. 2. The body weight of male is not less than 50kg, and female is not less than 45kg. All participants' body mass index (BMI) is between 19~26. 3. Subjects are fully informed and voluntarily consent to participate in this study. 4. Volunteers can communicate well with researchers and comply with the requirements of this study. Exclusion Criteria: 1. Any with chronic or active gastrointestinal diseases such as esophageal diseases, gastritis, gastric ulcers, enteritis, active gastrointestinal bleeding or got any digestive tract surgery within three years. 2. Any disease previously or currently suffering from circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry, and metabolic abnormalities, and which the researchers believe can interfere with the results of the test. 3. Any history of allergy to drugs, food, or other substances. 4. Dysphagia, difficulty in collecting blood or halo needle, history of dizziness. 5. Those who have undergone surgery during the first four weeks of the trial or are scheduled to perform surgery during the study period. 6. Those who has taken any drug (including vitamin products, Chinese herbs) within 14 days before the study. 7. Those who use any inhibits or induces hepatic metabolism within 30 days before the study. 8. Those who participated in any clinical drug trial within 3 months prior to the trial. 9. Those who donated or lose massive blood within 3 months before the study (> 450 ml). 10. Pregnant and lactating women. 11. Male subjects (or their partners) or female subjects had unprotected sex or pregnancy plans within 2 weeks before screening and 6 months after the end of the trial, Those who are unwilling to use one or more non-drug contraceptive methods (e. G. Complete abstinence, contraceptive ring, partner ligation, etc.) during the study. 12. Drug abusers or those who have used soft drugs for 3 months before the trial or who took hard drugs one year before the study. 13. Those who has special requirements for diet and is unable to follow a uniform diet. 14. Smokers or those who smoked more than 5 cigarettes a day 3 months before the study. 15. An alcoholic or regular drinker for six months before the study, that is, a person who drinks more than 14 units of alcohol a week. 16. People who drink excessive amounts of tea, coffee and/or caffeinated beverages (more than 8 cups, 1 cup =250 mL) per day or who do not agree to stop drinking tea, coffee and/or caffeinated beverages during the study period. 17. Those who take drug or food which may affect the drug metabolism(including grapefruit or grapefruit products, dragon fruit, mango, pomelo, orange, yellow purine diet).Or the researchers think that there are other affect drug absorption, distribution, metabolism and excretion of diet.Or refuse to stop eating the diet during the study. 18. Those with abnormal physical examination, electrocardiogram, laboratory examination, vital signs and test related examination with clinical significance . 19. Those who has vital signs with clinical significance, positive urine screening test, positive alcohol breath test or positive female urine pregnancy. 20. Those who has acute illness or concomitant medication occurred before participating in the study. 21. Other reasons which,in the opinion of the medical investigator,would prevent the subject from participating in the study. |
Country | Name | City | State |
---|---|---|---|
China | The Third Hospital of Changsha | Changsha | Hunan |
Lead Sponsor | Collaborator |
---|---|
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Peak Plasma Concentration (Cmax) | Maximum observed plasma concentration following drug administration from the raw plasma concentration-time data. | 0hours?0.67hours?1hours?1.5hours?2hours?2.5hours?3hours?4hours?6hours?8hours?12hours?24hours?36hours?48hours?72hours | |
Secondary | Area under the plasma concentration versus time curves (AUC) | Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration. | 0hours?0.67hours?1hours?1.5hours?2hours?2.5hours?3hours?4hours?6hours?8hours?12hours?24hours?36hours?48hours?72hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |